Sobi

A specialty healthcare company developing and delivering innovative therapies and services to treat rare diseases

Our view

  • Sobi has delivered strong operational performance and shareholder return over the last years.
  • The company’s strong performance has been driven by the successful launch of two haemophilia products in Europe. Sobi is providing
    new innovative treatments for haemophilia patients and was first to market outside the U.S. with a long-acting haemophilia A treatment,
    Elocta.
  • Going forward, continuing to build a strong and successful haemophilia franchise as well as broadening the product portfolio is key for the company.
Visit the company website

Company facts

Registered Office:

Stockholm, SWEDEN

Listed:

Stockholm, SWEDEN

Business Area:

Listed Core Investments

Share of total assets (%):

7

Ownership capital/votes (%):

39.4/39.4

Investment Year:

2009

Serving On The Board:

Lennart Johansson and Helena Saxon
investor pattern